نتائج البحث

1

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

المؤلفون: Adrian Wiestner, Christoph Rader, Junpeng Qi, David Eik, Maissa Mhibik, Amy Blackburn, Ellen K Kendall, Erika M Gaglione, Inhye E. Ahn, Keyvan Keyvanfar, Clare Sun, Maria Joao Baptista

المصدر: Blood

مصطلحات موضوعية: Adult, Male, CD3 Complex, Chronic lymphocytic leukemia, medicine.medical_treatment, CD3, T-Lymphocytes, Immunology, Antigens, CD19, Biochemistry, chemistry.chemical_compound, Antineoplastic Agents, Immunological, Antigen, Piperidines, Antibodies, Bispecific, medicine, Agammaglobulinaemia Tyrosine Kinase, Bruton's tyrosine kinase, Cytotoxic T cell, Humans, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Lymphoid Neoplasia, biology, business.industry, Adenine, Cell Biology, Hematology, Immunotherapy, Middle Aged, medicine.disease, Ipilimumab, Leukemia, Lymphocytic, Chronic, B-Cell, chemistry, Ibrutinib, Pyrazines, Benzamides, Cancer research, biology.protein, Acalabrutinib, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d35499edf8df936d2a9410e08289b05Test
https://europepmc.org/articles/PMC8586964Test/

2

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

المصدر: Blood. 136:93-105

مصطلحات موضوعية: Male, Chronic lymphocytic leukemia, Immunology, Pain, Phases of clinical research, Antineoplastic Agents, Pharmacology, Biochemistry, Drug Administration Schedule, immune system diseases, hemic and lymphatic diseases, Agammaglobulinaemia Tyrosine Kinase, Humans, Medicine, Bruton's tyrosine kinase, RNA, Messenger, RNA, Neoplasm, RNA-Seq, Dosing, Progression-free survival, Protein Kinase Inhibitors, Aged, Aged, 80 and over, biology, business.industry, Headache, Cell Biology, Hematology, Middle Aged, medicine.disease, Hematologic Diseases, Leukemia, Lymphocytic, Chronic, B-Cell, Progression-Free Survival, Neoplasm Proteins, Leukemia, Treatment Outcome, Enzyme Induction, Pyrazines, Pharmacodynamics, Benzamides, biology.protein, Acalabrutinib, Female, Transcriptome, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2ccd10671085e06e6fbd8849b4c0afTest
https://doi.org/10.1182/blood.2019003715Test

3

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

المساهمون: Furman, R. R., Byrd, J. C., Owen, R. G., O'Brien, S. M., Brown, J. R., Hillmen, P., Stephens, D. M., Chernyukhin, N., Lezhava, T., Hamdy, A. M., Izumi, R., Patel, P., Baek, M., Christian, B., Dyer, M. J. S., Streetly, M. J., Sun, C., Rule, S., Wang, M., Ghia, P., Jurczak, W., Pagel, J. M., Sharman, J. P.

المصدر: Leukemia. 35(11)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Nausea, Anemia, Antineoplastic Agents, Neutropenia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, Clinical Trials as Topic, business.industry, Hematology, Middle Aged, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, United States, Discontinuation, Survival Rate, Pneumonia, 030104 developmental biology, Upper respiratory tract infection, Oncology, Tolerability, 030220 oncology & carcinogenesis, Pyrazines, Benzamides, Female, medicine.symptom, business, Follow-Up Studies